X-Biotix Therapeutics, Inc., a Waltham, Mass.-based biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multi-drug-resistant (MDR) Gram-negative pathogens, secured $7m in Series A financing.
A group of private investors participated. The company also announced the addition of key individuals, including the appointment of Stephen T. Isaacs, and Christopher Ray to the Board of Directors, as well as Dominic Ryan, Ph.D. to the position of Chief Scientific Officer.
The company intends to use the proceeds to advance its pipeline of novel antibiotic candidates targeting a wide range of biological targets in essential pathways of Gram-negative bacterial cells.
Led by Ramani Varanasi, President & CEO, X-Biotix Therapeutics is a discovery, early preclinical-stage company that was spun out of X-Chem and incorporated in 2016, with a focus on delivering innovative antibiotics to combat multi-drug resistant Gram-negative pathogens. The company is undertaking a multi-target discovery strategy to identify and validate novel small molecule scaffolds and advance them into development.